Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) – SunTrust Banks boosted their FY2020 earnings estimates for shares of Supernus Pharmaceuticals in a report released on Tuesday. SunTrust Banks analyst J. Boris now expects that the brokerage will earn $3.95 per share for the year, up from their prior estimate of $3.92.

ILLEGAL ACTIVITY NOTICE: “SunTrust Banks Weighs in on Supernus Pharmaceuticals, Inc.’s FY2020 Earnings (SUPN)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be read at http://www.watchlistnews.com/suntrust-banks-weighs-in-on-supernus-pharmaceuticals-inc-s-fy2020-earnings-supn/1060641.html.

Earnings History and Estimates for Supernus Pharmaceuticals (NASDAQ:SUPN)

Several other equities analysts have also commented on the company. Zacks Investment Research upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $28.00 target price for the company in a research note on Friday, November 18th. Jefferies Group set a $28.00 target price on Supernus Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, October 13th. Finally, Cantor Fitzgerald started coverage on Supernus Pharmaceuticals in a research report on Friday, December 16th. They set an “overweight” rating and a $32.00 price target for the company. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Supernus Pharmaceuticals has an average rating of “Buy” and an average price target of $26.20.

Supernus Pharmaceuticals (NASDAQ:SUPN) traded up 0.80% during midday trading on Friday, reaching $25.10. The company’s stock had a trading volume of 349,279 shares. The company has a 50 day moving average of $23.78 and a 200-day moving average of $22.41. Supernus Pharmaceuticals has a 1-year low of $9.51 and a 1-year high of $27.50. The company has a market capitalization of $1.24 billion, a P/E ratio of 51.22 and a beta of 1.88.

Several large investors have recently modified their holdings of the company. Neuberger Berman Group LLC bought a new stake in shares of Supernus Pharmaceuticals during the second quarter valued at $387,000. State Board of Administration of Florida Retirement System increased its stake in shares of Supernus Pharmaceuticals by 15.3% in the second quarter. State Board of Administration of Florida Retirement System now owns 23,176 shares of the specialty pharmaceutical company’s stock valued at $472,000 after buying an additional 3,082 shares during the last quarter. EAM Investors LLC bought a new stake in shares of Supernus Pharmaceuticals during the second quarter valued at $3,835,000. Mutual of America Capital Management LLC increased its stake in shares of Supernus Pharmaceuticals by 1.8% in the second quarter. Mutual of America Capital Management LLC now owns 547,018 shares of the specialty pharmaceutical company’s stock valued at $11,143,000 after buying an additional 9,425 shares during the last quarter. Finally, Swiss National Bank increased its stake in shares of Supernus Pharmaceuticals by 15.5% in the second quarter. Swiss National Bank now owns 65,000 shares of the specialty pharmaceutical company’s stock valued at $1,324,000 after buying an additional 8,700 shares during the last quarter. 93.46% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: “SunTrust Banks Weighs in on Supernus Pharmaceuticals, Inc.’s FY2020 Earnings (SUPN)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this story on another site, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be read at http://www.watchlistnews.com/suntrust-banks-weighs-in-on-supernus-pharmaceuticals-inc-s-fy2020-earnings-supn/1060641.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. The Company offers products for the treatment of epilepsy, which include extended-release oxcarbazepine (Oxtellar XR) and extended-release topiramate (Trokendi XR).

5 Day Chart for NASDAQ:SUPN

Receive News & Ratings for Supernus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.